Octreotide: What the Evidence Actually Shows

Octreotide is a real, FDA-approved drug — first approved in 1988, decades before any peptide this site otherwise covers — and it belongs to a genuinely different part of the growth-hormone story than most of this corpus. Sermorelin and CJC-1295/ipamorelin both work by STIMULATING growth hormone release — mimicking the hypothalamic signal that tells the pituitary to release more GH. Octreotide does the opposite: it's a somatostatin analog, and somatostatin's entire biological job is to SUPPRESS growth hormone release. Read side by side, these are mechanistic mirror images of each other, not variations on a theme — and this article treats octreotide on those terms rather than lumping it in with the GH-stimulating peptides it's often mentioned alongside.

Two real, separately-approved products — not one drug with two strengths

A live openFDA Drugs@FDA check finds octreotide sold in the US as two distinct, separately-approved products, not one product with a dosing range. Sandostatin Injection — the immediate-release, ready-to-use ampule formulation — was originally approved October 21, 1988, under NDA019667, sponsored by Novartis¹. Sandostatin LAR Depot — a long-acting reformulation — is a separate application entirely, NDA021008, originally approved a full decade later, November 25, 1998¹. Independently cross-checked against DailyMed's own structured-product-label index: both remain live, current, separately-maintained labels today, most recently updated July 2026 (Sandostatin Injection) and December 2025 (Sandostatin LAR Depot)¹. That gap between the two approvals is not incidental — it tracks a genuine engineering problem: octreotide's native half-life is only about 90 minutes, and building a monthly depot version took Novartis a decade past the original injection's approval.

What it's actually approved for

Sandostatin Injection's current label lists exactly three indications, read directly from its own INDICATIONS AND USAGE section: acromegaly (to reduce GH and IGF-1 levels in patients who've had an inadequate response to or can't be treated with surgery, radiation, or bromocriptine), symptomatic treatment of metastatic carcinoid tumors (suppressing the severe diarrhea and flushing episodes the disease causes), and VIPomas (profuse watery diarrhea from VIP-secreting tumors)². The label is explicit about a limitation worth stating plainly: "Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin Injection²" — this is a symptom-control drug for these three indications, not a tumor-shrinking one, at least not by Sandostatin Injection's own pivotal-trial evidence.

Sandostatin LAR Depot's label mirrors those same three indications, but with an added gate: it's indicated specifically "in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated³" — meaning a patient starts on the immediate-release injection first, and only transitions to the once-monthly depot after that trial period confirms the drug works for them.

What the mechanism actually does — and why it's the opposite of sermorelin

Octreotide's own label describes its mechanism in terms worth reading precisely: "Sandostatin Injection exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and insulin than somatostatin²." It also suppresses the pituitary's LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, VIP, secretin, motilin, and pancreatic polypeptide² — a broad, deliberately inhibitory hormonal profile. That's the direct mechanistic opposite of sermorelin, which works by activating the GHRH receptor to trigger a GH pulse, and of CJC-1295 and ipamorelin, which extend and amplify that same stimulating signal through a GHRH analog paired with a ghrelin-receptor agonist. A patient taking octreotide for acromegaly is, in a real clinical sense, being treated for having too MUCH growth hormone signaling; a patient asking about sermorelin or CJC-1295/ipamorelin is typically looking to increase it. Same axis, opposite direction — worth understanding as a contrast, not conflating as "another GH peptide."

The dosing forms are genuinely different products, not a strength choice

Sandostatin Injection is subcutaneous or intravenous, dosed multiple times daily — 50 mcg three times daily to start for acromegaly, escalating to a 100-500 mcg three-times-daily maintenance range; 100-600 mcg daily in divided doses for carcinoid tumors; 200-300 mcg daily for VIPomas². It ships as a clear, ready-to-use solution in single-dose ampules — no reconstitution, no mixing.

Sandostatin LAR Depot is a different administration model entirely: an intramuscular gluteal injection given once every 4 weeks, using a fixed single-dose kit that contains a 10, 20, or 30 mg vial, a prefilled syringe with exactly 2 mL of diluent, a vial adapter, and a dedicated mixing needle³. The label is direct about who administers it and how: "SANDOSTATIN LAR DEPOT should be administered by a trained healthcare provider... must be administered immediately after mixing... should never be administered intravenously or subcutaneously³." There's no diluent-volume decision to make and no partial-vial dosing — the whole kit is mixed and given as one fixed intramuscular dose, which is why this site doesn't build a reconstitution-calculator page for it: the arithmetic this site's calculator tool exists to do (choosing a diluent volume, drawing a partial dose) doesn't apply to a fixed manufacturer kit administered by clinical staff.

A real off-label use worth naming precisely: variceal bleeding

The task behind this article specifically asked whether octreotide's well-known use for esophageal variceal bleeding is real, and if so, whether it's an approved indication. It is real and well-evidenced — and it is genuinely OFF-LABEL, not part of Sandostatin's current FDA indications. A 2021 systematic review and meta-analysis of 21 randomized controlled trials compared terlipressin/vasopressin against octreotide/somatostatin (grouped together as the trial literature itself groups them) for acute variceal bleeding, using GRADE methodology⁴. Mortality risk was statistically similar between the two drug classes (RR 1.01, 95% CI 0.83-1.22), and adverse events were significantly HIGHER with terlipressin/vasopressin than with octreotide/somatostatin (RR 2.39, 95% CI 1.58-3.63)⁴ — real, moderate-certainty evidence behind a genuinely common gastroenterology practice, reported here exactly as the source reports it: octreotide bundled with somatostatin as one comparator group, not isolated as its own arm.

A newer development worth flagging: a self-administered depot in Phase 3

Sandostatin LAR Depot's clinician-only, gluteal-injection requirement is a real burden for a drug meant to be taken monthly for years. A live check found real, current, published research addressing exactly that gap: CAM2029, a novel self-administered subcutaneous octreotide depot built on Camurus AB's FluidCrystal technology, was tested in ACROINNOVA 1 — a 24-week, multinational, randomized, double-blind, placebo-controlled Phase 3 trial (NCT04076462) in 72 patients with already-controlled acromegaly⁵. At week 22/24, 72.2% of CAM2029-treated patients maintained IGF-1 control versus 37.5% on placebo (P=.0018), with safety consistent with standard-of-care octreotide/lanreotide⁵. This is real, current, peer-reviewed evidence that room-temperature, at-home octreotide dosing is an active area of development — but a direct openFDA check found no approved application for CAM2029 under that name as of this review. It remains investigational, not an FDA-approved alternative to Sandostatin LAR Depot today.

What this means if you're considering it

Octreotide is a real, decades-established FDA drug for a narrow set of serious conditions — acromegaly, carcinoid tumor symptoms, and VIPomas — sold as two genuinely different, separately-approved products depending on whether daily injections or a monthly clinician-administered depot fits a patient's treatment plan. It is not a compounded or grey-market peptide, and no reviewed provider on this site's roster sells it. Its mechanism is worth understanding specifically because it cuts against the direction most of this site's other growth-hormone-axis content runs: where sermorelin and CJC-1295/ipamorelin stimulate GH release, octreotide suppresses it — the same axis, treated from the opposite direction, for a genuinely different clinical purpose.